Phase 1 Study on Safety and Immunogenicity of HIV SOSIP v8.2 763 Vaccine in Healthy Adults

The primary objective of this phase 1 clinical trial is to evaluate the **safety** and **immunogenicity** of the HIV SOSIP v8.2 763 vaccine in healthy individuals. This is clinically relevant as it aims to determine the vaccine's potential to elicit an immune response without causing adverse effects, which is crucial for the development of effective preventive strategies against **Human Immunodeficiency Virus (HIV)**. The study does not specify any secondary objectives.

The clinical trial involves participants diagnosed with **Human Immunodeficiency Virus (HIV)**. The study population includes both male and female subjects, with an age range categorized under code "3", which typically represents adults. The trial also includes a vulnerable population, although specific details regarding the vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. The sponsor has not provided information on key inclusion or exclusion criteria.

The clinical trial is a **phase 1** study designed to evaluate the safety and immunogenicity of the HIV SOSIP v8.2 763 vaccine in healthy individuals. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who receives the vaccine or a placebo, thus minimizing bias. The trial is expected to commence recruitment on July 24, 2023, and conclude by November 24, 2025, spanning an estimated duration of approximately 28 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for trial inclusion. Following successful screening, participants will be randomized and receive their first dose of the investigational product or placebo. Subsequent follow-up visits will be scheduled at regular intervals to monitor safety, collect blood samples for immunogenicity assessments, and document any adverse events. These visits are crucial for evaluating the vaccine's effects over time and ensuring participant safety.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, a final assessment will be conducted to gather comprehensive data on the participant's health status and any long-term effects of the vaccine. The expected length of participant involvement is contingent upon the trial's schedule, with each participant anticipated to be involved for the full duration unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, withdrawal of consent, or any other medical reasons deemed necessary by the study investigators.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided dataset. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is July 24, 2023, with an anticipated end date of November 24, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of pharmacokinetics and pharmacodynamics, which may include measuring biomarker levels or other relevant physiological responses. The methods for measuring and analyzing these parameters are not specified, but standard practices in Phase 1 trials often involve laboratory tests and validated scales. The trial's duration and phase suggest a focus on gathering preliminary data to inform subsequent phases of clinical research.